A shareholder group led by private equity firm Nordic Capital has agreed to sell The Binding Site Group (Binding Site), a specialty diagnostics company headquartered in Birmingham, UK, to Thermo Fisher Scientific for £2.25 billion.
Nordic Capital has been the majority owner of The Binding Site since 2011 when it completed the acquisition together with Five Arrows. Since then, the business has grown fivefold with revenues amounting to approximately £200 million in 2022.
The transaction, which is expected to be completed in the first half of 2023, is subject to customary closing conditions, including regulatory approvals.
Read more: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.